This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Spellberg, B.
Right arrow Articles by Ibrahim, A. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Spellberg, B.
Right arrow Articles by Ibrahim, A. S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 2009, p. 3122-3125, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.00361-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Safety and Outcomes of Open-Label Deferasirox Iron Chelation Therapy for Mucormycosis{triangledown}

Brad Spellberg,1,2* David Andes,3 Mario Perez,4 Anne Anglim,5 Hector Bonilla,6 Glenn E. Mathisen,7 Thomas J. Walsh,8 and Ashraf S. Ibrahim1,2

Division of Infectious Diseases, Los Angeles Biomedical Research Institute at Harbor-University of California at Los Angeles (UCLA) Medical Center, Torrance, California,1 the David Geffen School of Medicine at UCLA, Los Angeles, California,2 Departments of Medicine and Medical Microbiology and Immunology, University of Wisconsin School of Medicine, Madison, Wisconsin,3 Division of Infectious Diseases, University of Southern California (USC) School of Medicine Department of Medicine, Los Angeles, California,4 Long Beach Public Department of Health, Long Beach, California,5 Summa Health System, Akron, Ohio,6 Division of Infectious Diseases, Olive View-UCLA Medical Center, Sylmar, California,7 Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland8

Received 16 March 2009/ Returned for modification 21 April 2009/ Accepted 4 May 2009

We sought to describe the safety profile of open-label, adjunctive deferasirox iron chelation therapy in eight patients with biopsy-proven mucormycosis. Deferasirox was administered for an average of 14 days (range, 7 to 21) at 5 to 20 mg/kg of body weight/day. The only adverse effects attributable to deferasirox were rashes in two patients. Deferasirox treatment was not associated with changes in renal or liver function, complete blood count, or transplant immunosuppressive levels. Thus, deferasirox appears safe as an adjunctive therapy for mucormycosis.

* Corresponding author. Mailing address: 1124 West Carson St., RB2, Torrance, CA 90502. Phone: (310) 222-5381. Fax: (310) 782-2016. E-mail: bspellberg{at}labiomed.org

{triangledown} Published ahead of print on 11 May 2009.

Antimicrobial Agents and Chemotherapy, July 2009, p. 3122-3125, Vol. 53, No. 7
0066-4804/09/$08.00+0     doi:10.1128/AAC.00361-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»